Drug firm Indoco Remedies Ltd announced on Thursday (May 28) that its Oral Solid Dosage manufacturing facility at Baddi, Himachal Pradesh, has received EU GMP certification from the German Health Authority (Berlin). According to reports from CNBC TV18, the certification follows an inspection of the company's Plant III facility conducted from April 22, 2026, to April 27, 2026. The certification confirms that the facility complies with Good Manufacturing Practice requirements referred to in the EC Directive.
The company reported a net loss of ₹22 crore for the fourth quarter, compared with a loss of ₹40 crore in the corresponding period last year. As reported by CNBC TV18, revenue for the quarter rose 22% year-on-year to ₹476 crore from ₹390 crore earlier. Operationally, the company achieved a notable turnaround with EBITDA of ₹50.2 crore, compared to an EBITDA loss of ₹1 crore in the year-ago quarter. EBITDA margin stood at 10.6%, reflecting improved operating leverage and better business traction across key segments.
For the full financial year FY26, Indoco Remedies reported revenue of ₹1,633.5 crore, compared with ₹1,494.8 crore in the previous year. According to CNBC TV18, EBITDA margin for the year improved to 9.6%, with EBITDA at ₹157.2 crore versus ₹128 crore in the previous financial year. The board has recommended a dividend of ₹0.20 per equity share of face value ₹2 for FY26, subject to shareholder approval at the company's upcoming annual general meeting.
On Wednesday (May 27), shares of Indoco Remedies Ltd ended at ₹202.90, up by ₹9.05, or 4.67%, on the BSE. As reported by CNBC TV18, Managing Director Aditi Panandikar stated that "The EU GMP certification for our formulations manufacturing plant is a testament to our commitment to delivering high-quality products to patients across the globe." The certification represents a significant milestone for the company's European market access capabilities.
